Biovaxys Technology Corp (TSE:BIOV) has released an update.
Biovaxys Technology Corp. and SpayVac-for-Wildlife, Inc. have announced the initiation of field trials for a new single-dose, long-lasting contraceptive vaccine for farmed rainbow trout, aiming to improve commercial aquaculture yields and prevent interbreeding with wild populations. SpayVac’s vaccine, using BioVaxys’ patented delivery technology, is also set for future application in wildlife population management. The collaboration taps into the burgeoning global market for farmed fish, valued at over $306 billion.
For further insights into TSE:BIOV stock, check out TipRanks’ Stock Analysis page.
